hlx10
mAbexperimental
Clinical trial activity
110 trials · 42 clinical orgs · 0 marketing orgs
Phase 1
15
Phase 2
92
Phase 3
17
Phase 4
1
Earliest trial started Jan 1, 2018 (NCT03468751)
Timeline
Indications
Studied for
- Adenocarcinoma of Lung · Phase 2
- Ascites · Phase 2
- Athletic Performance · Phase 2
- Bevacizumab · Phase 2/Phase 3
- Biliary Tract Neoplasms · Phase 2
- Brain Neoplasms · Phase 2/Phase 3
- Breast Neoplasms · Phase 2
- Carcinoma · Phase 3
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Neuroendocrine · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Small Cell · Phase 2
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 3
- DNA Mismatch Repair · Phase 2
- Drug Therapy · Phase 1
- Esophageal Neoplasms · Phase 2
- Esophageal Squamous Cell Carcinoma · Phase 4
- Genes, ras · Phase 2
- Hepatitis B, Chronic · Phase 2
- Immune Checkpoint Inhibitors · Phase 2
- Immunotherapy · Phase 3
- Lung Neoplasms · Phase 2
- Mutation · Phase 2
- Nasopharyngeal Carcinoma · Phase 3
- Nasopharyngeal Neoplasms · Phase 2
- Neoadjuvant Therapy · Phase 2
- Neoplasm Metastasis · Phase 2/Phase 3
- Neoplasms · Phase 2
- Neoplasm Staging · Phase 2
- Pancreatic Neoplasms · Phase 3
- Radiotherapy · Phase 3
- Rectal Neoplasms · Phase 2/Phase 3
- Self Efficacy · Phase 2
- Small Cell Lung Carcinoma · Phase 3
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 3
- Survival · Phase 2
- T-Lymphocytes · Phase 1
- Triple Negative Breast Neoplasms · Phase 3
- Uterine Cervical Neoplasms · Phase 3
- Vascular Endothelial Growth Factor A · Phase 2
Mechanism of action
- Programmed cell death protein 1ANTAGONIST
Programmed cell death protein 1 antagonist
- 80S RibosomeINHIBITOR
80S Ribosome inhibitor
- 60S ribosomal protein L39 (RPL39) ↗
- 60S ribosomal protein L41 (RPL41) ↗
- 40S ribosomal protein S15 (RPS15) ↗
- 40S ribosomal protein S15a (RPS15A) ↗
- 40S ribosomal protein S16 (RPS16) ↗
- 40S ribosomal protein S17 (RPS17) ↗
- 40S ribosomal protein SA (RPSA) ↗
- 40S ribosomal protein S18 (RPS18) ↗
- 40S ribosomal protein S19 (RPS19) ↗
- 40S ribosomal protein S20 (RPS20) ↗
- 40S ribosomal protein S21 (RPS21) ↗
- 40S ribosomal protein S23 (RPS23) ↗
- 40S ribosomal protein S24 (RPS24) ↗
- 40S ribosomal protein S25 (RPS25) ↗
- 40S ribosomal protein S27 (RPS27) ↗
- 40S ribosomal protein S26 (RPS26) ↗
- Ubiquitin-40S ribosomal protein S27a (RPS27A) ↗
- 40S ribosomal protein S28 (RPS28) ↗
- 40S ribosomal protein S29 (RPS29) ↗
- 40S ribosomal protein S30 (RS30) ↗
- 60S ribosomal protein L21 (RPL21) ↗
- 60S ribosomal protein L22 (RPL22) ↗
- 60S ribosomal protein L23 (RPL23) ↗
- 60S ribosomal protein L23a (RPL23A) ↗
- 60S ribosomal protein L24 (RPL24) ↗
- 40S ribosomal protein S6 (RPS6) ↗
- 60S ribosomal protein L26 (RPL26) ↗
- 60S ribosomal protein L27 (RPL27) ↗
- 60S ribosomal protein L27a (RPL27A) ↗
- 60S ribosomal protein L28 (RPL28) ↗
- 60S ribosomal protein L29 (RPL29) ↗
- 60S ribosomal protein L30 (RPL30) ↗
- 60S ribosomal protein L31 (RPL31) ↗
- 60S ribosomal protein L32 (RPL32) ↗
- 60S ribosomal protein L34 (RPL34) ↗
- 60S ribosomal protein L35 (RPL35) ↗
- 60S ribosomal protein L35a (RPL35A) ↗
- 60S ribosomal protein L36 (RPL36) ↗
- 60S ribosomal protein L36a (RPL36A) ↗
- 60S ribosomal protein L37 (RPL37) ↗
- 40S ribosomal protein S10 (RPS10) ↗
- 40S ribosomal protein S11 (RPS11) ↗
- 40S ribosomal protein S12 (RPS12) ↗
- 40S ribosomal protein S13 (RPS13) ↗
- 40S ribosomal protein S14 (RPS14) ↗
- 60S ribosomal protein L37a (RPL37A) ↗
- 40S ribosomal protein S2 (RPS2) ↗
- 40S ribosomal protein S3 (RPS3) ↗
- 40S ribosomal protein S3a (RPS3A) ↗
- 40S ribosomal protein S4, X isoform (RPS4X) ↗
- 40S ribosomal protein S4, Y isoform 1 (RPS4Y1) ↗
- 40S ribosomal protein S5 (RPS5) ↗
- 40S ribosomal protein S7 (RPS7) ↗
- 40S ribosomal protein S8 (RPS8) ↗
- 40S ribosomal protein S9 (RPS9) ↗
- 60S ribosomal protein L3 (RPL3) ↗
- 60S ribosomal protein L4 (RPL4) ↗
- 60S ribosomal protein L5 (RPL5) ↗
- 60S ribosomal protein L6 (RPL6) ↗
- 60S ribosomal protein L7 (RPL7) ↗
- 60S ribosomal protein L7a (RPL7A) ↗
- 60S ribosomal protein L8 (RPL8) ↗
- 60S ribosomal protein L9 (RPL9; RPL9P7; RPL9P8; RPL9P9) ↗
- 60S ribosomal protein L10 (RPL10) ↗
- 60S ribosomal protein L10a (RPL10A) ↗
- 60S ribosomal protein L11 (RPL11) ↗
- 60S ribosomal protein L12 (RPL12) ↗
- 60S ribosomal protein L13 (RPL13) ↗
- 60S ribosomal protein L13a (RPL13A) ↗
- 60S ribosomal protein L14 (RPL14) ↗
- 60S ribosomal protein L15 (RPL15) ↗
- 60S ribosomal protein L17 (RPL17) ↗
- 60S ribosomal protein L18 (RPL18) ↗
- 60S ribosomal protein L18a (RPL18A) ↗
- 60S ribosomal protein L19 (RPL19) ↗
- 60S ribosomal protein L38 (RPL38) ↗
- 60S acidic ribosomal protein P0 (RPLP0) ↗
- 60S acidic ribosomal protein P1 (RPLP1) ↗
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594550 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07283692 | Phase 2 | Dec 31, 2025 | Jiao Tong University |
| NCT07141771 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2025 | Chinese Academy of Medical Sciences |
| NCT07277842 | Phase 3 | Dec 29, 2025 | Sun Yat-Sen University |
| NCT07231445 | Phase 1 | Dec 23, 2025 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT07172412 | Phase 2 | Nov 30, 2025 | Tianjin Medical University |
| NCT07235930 | Phase 3 | Nov 15, 2025 | Chinese Academy of Medical Sciences |
| NCT07064876 | Phase 2 | Oct 31, 2025 | Fudan University |
| NCT07134218 | Phase 2/Phase 3 (Phase 3) | Oct 31, 2025 | Changhai Hospital |
| NCT07175389 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2025 | Sichuan University |
| NCT07177443 | Phase 3 | Sep 25, 2025 | Huazhong University of Science and Technology |
| NCT07155122 | Phase 2 | Sep 1, 2025 | Fujian Medical University |
| NCT07134101 | Phase 2 | Sep 1, 2025 | Nanjing Medical University |
| NCT07150949 | Phase 2 | Aug 28, 2025 | Fudan University |
| NCT06850103 | Phase 2 | Mar 28, 2025 | Zhejiang University |
| NCT06860529 | Phase 2 | Mar 1, 2025 | Henan Medical University |
| NCT06848699 | Phase 1/Phase 2 (Phase 2) | Feb 27, 2025 | Shanghai Henlius Biotech |
| NCT07257575 | Phase 2 | Jan 5, 2025 | Shanghai Henlius Biotech, Shantou University |
| NCT06692491 | Phase 2 | Jan 1, 2025 | Peking University |
| NCT06716619 | Phase 1 | Dec 20, 2024 | Guangzhou FineImmune Biotechnology Co., LTD., Sun Yat-Sen University |
| NCT06727617 | Phase 2 | Nov 19, 2024 | Tianjin Medical University |
Showing 20 of 110 trials
Page 1 / 6
Organizations
Research & Development (42)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Henlius Biotech | For profit | 31 | 29 | 3 | 2018 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 12 | 9 | 2 | 2019 |
| Fudan University | Academic/Hospital | 11 | 8 | 1 | 2021 |
| Sun Yat-Sen University | Academic/Hospital | 8 | 6 | 4 | 2023 |
| Zhejiang University | Academic/Hospital | 8 | 8 | 1 | 2022 |
| Jiao Tong University | Academic/Hospital | 6 | 6 | 2 | 2023 |
| Tianjin Medical University | Academic/Hospital | 6 | 5 | 1 | 2022 |
| Fujian Medical University | Academic/Hospital | 5 | 5 | 1 | 2023 |
| Huazhong University of Science and Technology | Academic/Hospital | 5 | 3 | 2 | 2020 |
| Central South University | Academic/Hospital | 4 | 0 | 2 | 2020 |
| Henan Medical University | Academic/Hospital | 4 | 4 | 2 | 2023 |
| Guangzhou Medical University | Academic/Hospital | 3 | 2 | 2 | 2024 |
| People's Liberation Army of China | Government | 3 | 2 | 2 | 2023 |
| Shantou University | Academic/Hospital | 3 | 2 | 1 | 2023 |
| Sichuan University | Academic/Hospital | 3 | 3 | 2 | 2023 |
| Xijing Hospital | Academic/Hospital | 3 | 2 | 3 | 2023 |
| Guangzhou FineImmune Biotechnology Co., LTD. | Government | 2 | 2 | 1 | 2023 |
| Henlix, Inc | For profit | 2 | 2 | 2 | 2018 |
| Nanjing Medical University | Academic/Hospital | 2 | 2 | 1 | 2023 |
| Peking University | Academic/Hospital | 2 | 1 | 1 | 2020 |
42 organizations
Page 1 / 3